The effects of glycine on auditory mismatch negativity in schizophrenia

Lisa-Marie Greenwood, Sumie Leung, Patricia T. Michie, Amity Green, Pradeep J. Nathan, Paul Fitzgerald, Patrick Johnston, Nadia Solowij, Jayashri Kulkarni, Rodney J. Croft

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Glycine increases N-methyl-d-aspartate receptor (NMDAR) mediated glutamatergic function. Mismatch negativity (MMN) is a proposed biomarker of glutamate-induced improvements in clinical symptoms, however, the effect of glycine-mediated NMDAR activation on MMN in schizophrenia is not well understood. This study aimed to determine the effects of acute and 6-week chronic glycine administration on MMN in schizophrenia patients. MMN amplitude was compared at baseline between 22 patients (schizophrenia or schizoaffective disorder; receiving stable antipsychotic medication; multi-centre recruitment) and 21 age- and gender-matched controls. Patients underwent a randomised, double-blind, placebo-controlled clinical trial with glycine added to their regular antipsychotic medication (placebo, n = 10; glycine, n = 12). MMN was reassessed post-45-minutes of first dose (0.2. g/kg) and post-6-weeks treatment (incremented to 0.6. g/kg/day). Clinical symptoms were assessed at baseline and post-6-weeks treatment. At baseline, duration MMN was smaller in schizophrenia compared to controls. Acute glycine increased duration MMN (compared to placebo), whilst this difference was absent post-6-weeks treatment. Six weeks of chronic glycine administration improved PANSS-Total, PANSS-Negative and PANSS-General symptoms compared to placebo. Smaller baseline duration MMN was associated with greater PANSS-Negative symptoms and predicted (at trend level) PANSS-Negative symptom improvement post-6-weeks glycine treatment (not placebo). These findings support the benefits of chronic glycine administration and demonstrate, for the first time, that acute glycine improves duration MMN in schizophrenia. This result, together with smaller baseline duration MMN predicting greater clinical treatment response, suggests the potential for duration MMN as a biomarker of glycine-induced improvements in negative symptoms in schizophrenia.

Original languageEnglish
Pages (from-to)61-69
Number of pages8
JournalSchizophrenia Research
Volume191
DOIs
Publication statusPublished - Jan 2018

Keywords

  • Glycine
  • Mismatch negativity
  • N-methyl-d-aspartate
  • Negative symptoms
  • Schizophrenia

Cite this

Greenwood, Lisa-Marie ; Leung, Sumie ; Michie, Patricia T. ; Green, Amity ; Nathan, Pradeep J. ; Fitzgerald, Paul ; Johnston, Patrick ; Solowij, Nadia ; Kulkarni, Jayashri ; Croft, Rodney J. / The effects of glycine on auditory mismatch negativity in schizophrenia. In: Schizophrenia Research. 2018 ; Vol. 191. pp. 61-69.
@article{49c4f4eff00d4552b306e7c3a96095b6,
title = "The effects of glycine on auditory mismatch negativity in schizophrenia",
abstract = "Glycine increases N-methyl-d-aspartate receptor (NMDAR) mediated glutamatergic function. Mismatch negativity (MMN) is a proposed biomarker of glutamate-induced improvements in clinical symptoms, however, the effect of glycine-mediated NMDAR activation on MMN in schizophrenia is not well understood. This study aimed to determine the effects of acute and 6-week chronic glycine administration on MMN in schizophrenia patients. MMN amplitude was compared at baseline between 22 patients (schizophrenia or schizoaffective disorder; receiving stable antipsychotic medication; multi-centre recruitment) and 21 age- and gender-matched controls. Patients underwent a randomised, double-blind, placebo-controlled clinical trial with glycine added to their regular antipsychotic medication (placebo, n = 10; glycine, n = 12). MMN was reassessed post-45-minutes of first dose (0.2. g/kg) and post-6-weeks treatment (incremented to 0.6. g/kg/day). Clinical symptoms were assessed at baseline and post-6-weeks treatment. At baseline, duration MMN was smaller in schizophrenia compared to controls. Acute glycine increased duration MMN (compared to placebo), whilst this difference was absent post-6-weeks treatment. Six weeks of chronic glycine administration improved PANSS-Total, PANSS-Negative and PANSS-General symptoms compared to placebo. Smaller baseline duration MMN was associated with greater PANSS-Negative symptoms and predicted (at trend level) PANSS-Negative symptom improvement post-6-weeks glycine treatment (not placebo). These findings support the benefits of chronic glycine administration and demonstrate, for the first time, that acute glycine improves duration MMN in schizophrenia. This result, together with smaller baseline duration MMN predicting greater clinical treatment response, suggests the potential for duration MMN as a biomarker of glycine-induced improvements in negative symptoms in schizophrenia.",
keywords = "Glycine, Mismatch negativity, N-methyl-d-aspartate, Negative symptoms, Schizophrenia",
author = "Lisa-Marie Greenwood and Sumie Leung and Michie, {Patricia T.} and Amity Green and Nathan, {Pradeep J.} and Paul Fitzgerald and Patrick Johnston and Nadia Solowij and Jayashri Kulkarni and Croft, {Rodney J.}",
year = "2018",
month = "1",
doi = "10.1016/j.schres.2017.05.031",
language = "English",
volume = "191",
pages = "61--69",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",

}

The effects of glycine on auditory mismatch negativity in schizophrenia. / Greenwood, Lisa-Marie; Leung, Sumie; Michie, Patricia T.; Green, Amity; Nathan, Pradeep J.; Fitzgerald, Paul; Johnston, Patrick; Solowij, Nadia; Kulkarni, Jayashri; Croft, Rodney J.

In: Schizophrenia Research, Vol. 191, 01.2018, p. 61-69.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The effects of glycine on auditory mismatch negativity in schizophrenia

AU - Greenwood, Lisa-Marie

AU - Leung, Sumie

AU - Michie, Patricia T.

AU - Green, Amity

AU - Nathan, Pradeep J.

AU - Fitzgerald, Paul

AU - Johnston, Patrick

AU - Solowij, Nadia

AU - Kulkarni, Jayashri

AU - Croft, Rodney J.

PY - 2018/1

Y1 - 2018/1

N2 - Glycine increases N-methyl-d-aspartate receptor (NMDAR) mediated glutamatergic function. Mismatch negativity (MMN) is a proposed biomarker of glutamate-induced improvements in clinical symptoms, however, the effect of glycine-mediated NMDAR activation on MMN in schizophrenia is not well understood. This study aimed to determine the effects of acute and 6-week chronic glycine administration on MMN in schizophrenia patients. MMN amplitude was compared at baseline between 22 patients (schizophrenia or schizoaffective disorder; receiving stable antipsychotic medication; multi-centre recruitment) and 21 age- and gender-matched controls. Patients underwent a randomised, double-blind, placebo-controlled clinical trial with glycine added to their regular antipsychotic medication (placebo, n = 10; glycine, n = 12). MMN was reassessed post-45-minutes of first dose (0.2. g/kg) and post-6-weeks treatment (incremented to 0.6. g/kg/day). Clinical symptoms were assessed at baseline and post-6-weeks treatment. At baseline, duration MMN was smaller in schizophrenia compared to controls. Acute glycine increased duration MMN (compared to placebo), whilst this difference was absent post-6-weeks treatment. Six weeks of chronic glycine administration improved PANSS-Total, PANSS-Negative and PANSS-General symptoms compared to placebo. Smaller baseline duration MMN was associated with greater PANSS-Negative symptoms and predicted (at trend level) PANSS-Negative symptom improvement post-6-weeks glycine treatment (not placebo). These findings support the benefits of chronic glycine administration and demonstrate, for the first time, that acute glycine improves duration MMN in schizophrenia. This result, together with smaller baseline duration MMN predicting greater clinical treatment response, suggests the potential for duration MMN as a biomarker of glycine-induced improvements in negative symptoms in schizophrenia.

AB - Glycine increases N-methyl-d-aspartate receptor (NMDAR) mediated glutamatergic function. Mismatch negativity (MMN) is a proposed biomarker of glutamate-induced improvements in clinical symptoms, however, the effect of glycine-mediated NMDAR activation on MMN in schizophrenia is not well understood. This study aimed to determine the effects of acute and 6-week chronic glycine administration on MMN in schizophrenia patients. MMN amplitude was compared at baseline between 22 patients (schizophrenia or schizoaffective disorder; receiving stable antipsychotic medication; multi-centre recruitment) and 21 age- and gender-matched controls. Patients underwent a randomised, double-blind, placebo-controlled clinical trial with glycine added to their regular antipsychotic medication (placebo, n = 10; glycine, n = 12). MMN was reassessed post-45-minutes of first dose (0.2. g/kg) and post-6-weeks treatment (incremented to 0.6. g/kg/day). Clinical symptoms were assessed at baseline and post-6-weeks treatment. At baseline, duration MMN was smaller in schizophrenia compared to controls. Acute glycine increased duration MMN (compared to placebo), whilst this difference was absent post-6-weeks treatment. Six weeks of chronic glycine administration improved PANSS-Total, PANSS-Negative and PANSS-General symptoms compared to placebo. Smaller baseline duration MMN was associated with greater PANSS-Negative symptoms and predicted (at trend level) PANSS-Negative symptom improvement post-6-weeks glycine treatment (not placebo). These findings support the benefits of chronic glycine administration and demonstrate, for the first time, that acute glycine improves duration MMN in schizophrenia. This result, together with smaller baseline duration MMN predicting greater clinical treatment response, suggests the potential for duration MMN as a biomarker of glycine-induced improvements in negative symptoms in schizophrenia.

KW - Glycine

KW - Mismatch negativity

KW - N-methyl-d-aspartate

KW - Negative symptoms

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85020294471&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2017.05.031

DO - 10.1016/j.schres.2017.05.031

M3 - Article

VL - 191

SP - 61

EP - 69

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

ER -